文献速递脑血管病

急性卒中试验中延迟知情同意的患者认知与态度调查

Deferral of Consent in Acute Stroke Trials.
PubMed 文献 · Stroke · 2019-01-01

该研究基于ESCAPE试验,调查以延迟知情同意入组的急性缺血性卒中患者或其授权第三方对知情同意过程的认知与看法。56例延迟同意入组患者中33例完成初始问卷、27例完成90天随访,结果显示多数受访者理解试验基本原则,但普遍不认可在急性卒中试验中使用延迟知情同意。

要点

  • 延迟知情同意未显著改变ESCAPE试验的门至随机化时间。
  • 仅52%受访者理解患者可能被随机分配至取栓或标准治疗。
  • 多数受访者在基线与90天均不认可急性卒中试验采用延迟知情同意。

核心结论

  • 受访者总体上不认可在ESCAPE试验及更广泛的卒中试验中使用延迟知情同意入组。

研究设计与样本

  • 基于ESCAPE多中心随机对照试验(血管内取栓对比标准治疗)的调查研究,纳入全部56例以延迟知情同意入组的患者或其授权第三方。
  • 在入组后前4天及90天分别完成12个问题的问卷,调查对ESCAPE试验的认知及对延迟知情同意的看法。

主要发现

  • 56例延迟同意入组患者中33例(59%)完成初始问卷,其中27例(81%)完成90天随访。
  • 延迟知情同意入组与门至随机化时间无显著差异(50.5分钟对比57分钟;P=0.29),但使这56例患者得以参与试验。
  • 仅52%受访者理解患者可能被随机分配至取栓或标准治疗,多数理解试验其他基本原则。
  • 基线与90天时,受访者对急性卒中试验普遍采用延迟知情同意表示不同意或强烈不同意(82%与78%),对ESCAPE试验本身亦如此(93%与91%)。

临床怎么用

  • 在急性卒中试验设计延迟知情同意流程时,需重视患者及授权第三方的事后告知与沟通,因其接受度可能较低。

局限性

  • 样本量小(56例入组,33例完成初始问卷,27例完成90天随访),问卷完成率有限,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- The ESCAPE trial (The Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times) was a multicentre, randomized controlled trial of endovascular thrombectomy versus standard care for patients with acute ischemic stroke that allowed patients to be enrolled with deferred consent. We investigated the knowledge and opinions of these patients or their authorized third parties about the consent process. Methods- All patients (or their authorized third parties) enrolled with deferral of consent in ESCAPE were invited to complete a 12-question survey within the first 4 days of enrollment and again at 90 days. Questions investigated knowledge of the ESCAPE trial and opinions on deferral of consent. Results- Of 56 patients enrolled with deferred consent, 33 (59%) completed the initial survey, and of these, 27 (81%) completed the 90-day follow-up. Enrollment with deferred consent was not associated with a significant difference in door-to-randomization times (50.5 versus 57 minutes; P=0.29) but allowed these 56 patients to participate in the trial. Only 52% of respondents understood that patients could be randomized to thrombectomy or standard care, although most understood the other basic principles of the trial. At baseline and at 90 days, respondents disagreed or strongly disagreed with deferred consent in acute stroke trials generally (82% and 78%) and in the ESCAPE trial specifically (93% and 91%). Conclusions- Respondents generally disagreed with the use of deferred consent for enrollment in the ESCAPE trial and in stroke trials more generally.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Shamy MCF, Dewar B, Chevrier S, et al. Deferral of Consent in Acute Stroke Trials. Stroke. 2019. PMID: 30869570. doi:10.1161/STROKEAHA.118.024096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。